カレントテラピー　32-4　サンプル page 25/30

このページは カレントテラピー　32-4　サンプル の電子ブックに掲載されている25ページの概要です。
秒後に電子ブックの対象ページへ移動します。
「電子ブックを開く」をクリックすると今すぐ対象ページへ移動します。

概要：
カレントテラピー　32-4　サンプル

Current Therapy 2014 Vol.32 No.4 75治療薬解説391Invest 117：246-257, 20079）Weir GC, Bonner-Weir S：A dominant role for glucose inbeta cell compensation of insulin resistance. J Clin Invest117：81-83, 200710）Nakamura A, Terauchi Y, Ohyama S, et al：Impact of smallmoleculeglucokinase activator on glucose metabolism andbeta-cell mass. Endocrinology 150：1147-1154, 200911）Shirakawa J, Togashi Y, Sakamoto E, et al：Glucokinase activationameliorates ER stress-induced apoptosis in pancreaticβ-cells. Diabetes 62：3448-3458, 201312）Bonadonna RC, Heise T, Arbet-Engels C, et al：Piragliatin（RO4389620）, a novel glucokinase activator, lowers plasmaglucose both in the postabsorptive state and after a glucosechallenge in patients with type 2 diabetes mellitus：a mechanisticstudy. J Clin Endocrinol Metab 95：5028-5036, 201013）Meininger GE, Scott R, Alba M, et al：Effects of MK-0941, anovel glucokinase activator, on glycemic control in insulintreatedpatients with type 2 diabetes. Diabetes Care 34：2560-2566, 201114）Ahren B：Islet G protein-coupled receptors as potential targetsfor treatment of type 2 diabetes. Nat Rev Drug Discov8：369-385, 200915）Tsujihata Y, Ito R, Suzuki M, et al：TAK -875, an orallyavailable G protein -coupled receptor 40/free fatty acidreceptor 1 agonist, enhances glucose -dependent insulinsecretion and improves both postprandial and fasting hyperglycemiain type 2 diabetic rats. J Pharmacol Exp Ther339：228-237, 201116）Burant CF, Viswanathan P, Marcinak J, et al：TAK-875 versusplacebo or glimepiride in type 2 diabetes mellitus：aphase 2, randomised, double-blind, placebo-controlled trial.Lancet 379：1403-1411, 201217）Araki T, Hirayama M, Hiroi S, et al：GPR40-induced insulinsecretion by the novel agonist TAK-875：first clinical findingsin patients with type 2 diabetes. Diabetes Obes Metab14：271-278, 201218）Chu ZL, Jones RM, He H, et al：A role for beta - cell -expressed G protein-coupled receptor 119 in glycemic controlby enhancing glucose - dependent insulin release.Endocrinology 148：2601-2609, 200719）Nunez DJ, et al：Evaluation of GSK1292263, a Novel GPR119Agonist, in Type 2 Diabetes Mellitus（T2DM）：Safety,Tolerability, Pharmacokinetics（PK）and Pharmacodynamics（PD）of Single and Multiple doses. Diabetes 60（Suppl 1）：A273, 201120）Goodman ML, et al：The Novel GPR119-Receptor AgonistPSN821 Shows Glucose Lowering and Decreased EnergyIntake in Patients with T2DM after 14 Days Treatment.Diabetes 60（Suppl 1）：A84, 2011